Beactica Therapeutics’ small molecule platform enables the efficient development of innovative drug candidates

With its powerful and versatile platform, Beactica Therapeutics identifies innovative small molecule drug candidates that have a targeted effect against carefully selected disease proteins. Strategic collaborations provide access to valuable knowledge and opportunities to work with a broader portfolio. We speak to the company's CEO, Dr Per Källblad.

Read the full original Swedish article here, and the translation in English here.

See all recent coverage